141例原發(fā)性膽汁性膽管炎臨床特征分析
[Abstract]:Objective: To observe and analyze the clinical data of 141 patients diagnosed as primary biliary cholangitis (PBC) in our hospital (general data, clinical manifestation, blood biochemistry, autoantibody, imaging examination, etc.) and their characteristics, to explore the relationship between anti Ro-52 antibody and PBC, and to refer to the related indications of esophageal / gastric varices in PBC patients. Evaluation of the diagnostic value to further improve the understanding of the disease. Methods: 141 patients with complete cases of cholangitis diagnosed in our hospital in 2011, ~2016, ~2016 December, were diagnosed as general data, clinical symptoms and signs, clinical complications and complications, serum biochemical indexes, autoantibodies, and endoscopy. Review, imaging examination and Fibro Scan examination data. The same patient was hospitalized for the first time in hospitalization. Results: 1. men were 26 (18.4%) and 115 women (81.6%). The male and female ratio was 1:4.42, the average age of all cases was (57.8 + 10.8) years, the course of disease was 240 (60-700) days, and the hospital days were 11 (8-15) days.2. Ben. The common clinical manifestations of PBC patients: jaundice, hepatomegaly, asthenia, anorexia, upper abdominal discomfort, ascites, skin itching, dry mouth, edema of the lower extremities, and spider nevus of the liver, including electrolyte disorder (37 cases), gastrointestinal bleeding (20 cases), infection (14 cases), hepatic encephalopathy (2 cases); main complication: drying synthesis Syndrome (Sjogren's syndrome 11), diabetes (6 cases), Hashimoto's thyroiditis (5 cases), rheumatoid arthritis (1 cases), systemic lupus erythematosus (1 cases), adult STILL disease (1 cases), systemic sclerosis (1 cases) of.4.PBC patients with ALP and GGT elevation as the main [261.6 (155.5-489.1) U/L, 179.1 (81.0-430.5) U/L], and in the early stage of disease. Gao Xian was not significantly higher at the late stage; AST, ALT slightly elevated [69.0 (43.0-114.0) U/L, 54 (32.0-93.5) U/L], serum total bilirubin 30.5 (19.2-64.6) umol/L, the normal upper limit, the total bile acid TBA 20.1 (8.5-45.8) umol/L, 2 times higher than the normal upper limit, 3.1 (6) autoantibody examination, 91 cases (6) positive. 4.5%) AMA-M2 positive 120 cases (85.1%), 125 (88.7%) patients with ANA positive, 31 (22%) anti filal B antibody positive, 66 (46.8%) anti Ro-52 antibody positive, 22 cases (15.6%) SSA antibody positive, 15 (10.6%) SSB positive.6. research subjects in total 65 cases, there are esophageal varices in patients with esophageal varices and gastric fundus veins 8 cases (12.3%) showed ulcers and (or) erosion, 8 cases (12.3%) had portal hypertensive gastropathy, 29 cases (44.6%) showed chronic gastritis.8 (12.3%) with esophageal varices and fundus varicose.7. in 118 patients with abdominal ultrasound, 98 (83.1%) liver diffuse lesions, 38 (32.2%) ascites, 81 cases (68.6%)). In hepatomegaly, 35 cases (29.7%) showed portal / splenic vein widening or decreased flow rate, 5 cases (4.2%) cholestasis, 4 cases (3.4%) indicating portal vein thrombosis; 6 cases (5.1%) ultrasound examination normal. There were 41 patients with upper abdominal CT scan or plain scan. The results suggested that 25 cases (61%) cirrhosis, 14 cases (34.2%) suggest ascites, and there are 29 cases. In the liver and spleen, 7 cases (17.1%) showed portal hypertension, 19 cases (46.3%) were suggestive of esophageal varices, 16 cases (39%) were suggestive of varicose gastric fundus vein. There were 8 cases (19.5%) with esophageal gastroscope varicose and fundus varicose.8. in 26 patients with Fibro Scan examination. The results suggested that 9 patients (34.6%) were in the stage of cirrhosis. 14 (14) patients were in the period of cirrhosis. 1 patients with Mayo score, the mean value of 5.7 + 1.5.Mayo risk score and Fibro Scan staging have significant positive correlation (correlation coefficient 0.948, P value 0).9. male course 150 (30-361) compared with female group course 300 (60-1000) short, statistical difference (P= 0.023).AMA in female group (68.7%) detection rate is higher than male group (46.2%), difference There were statistical differences. There was no significant difference between the two groups in the clinical and biochemical examination. The.10.Ro-52 positive group was more prone to dry mouth dry mouth, ascites, with statistical difference (P respectively 0.014 and 0.012); positive combination and Sjogren syndrome were more than negative groups, there were statistical differences (P=0.002); positive group; positive group The serum Ig G was higher than that of the negative group (P value 0.023), but CHE was lower (P=0.008).11. for the diagnostic value of esophageal varices, when the Mayo score was equal to 4.8, the platelet count was 130 x 109/L, the serum albumin 38.6g/L was the largest, and the three had a certain diagnostic value for the esophageal varices. Total bilirubin and coagulation were of certain value. The diagnostic value of venous varicose in the time of blood enzyme is limited. Conclusion: primary biliary cholangitis mainly involves middle-aged women, and female patients have longer course of disease. The main manifestations are jaundice, liver and spleen, asthenia, anorexia, abdominal discomfort, ascites, skin itching, dry mouth and dry mouth, symptoms lack specificity, early part of the patients have no obvious symptoms, to disease in early part of the patients to disease. Later complications of liver cirrhosis accompanied by autoimmune diseases such as Sjogren's syndrome. The most diagnostic value of the non invasive examination was the serum AMA/AMA-M2 antibody. The Ro-52 positive group was more likely to merge with Sjogren syndrome. The antibody in the patient's sera was more prone to abdominal water, and the Ro-52 negative patients may have lower liver function. When the Mayo score is greater than 4.8, the platelet count is less than 130 x 109/L, the patients with serum albumin less than 38.6g/L need to follow up the gastroscopy regularly. At present, the treatment is based on UCDA, and it is necessary to find a more effective and safe method for early diagnosis of early treatment.
【學(xué)位授予單位】:蘭州大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2017
【分類號(hào)】:R575.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 鄧紅梅;胡世玲;陳維賢;黃英;;抗核孔膜蛋白和抗核體蛋白抗體對原發(fā)性膽汁性肝硬化診斷價(jià)值的meta分析[J];中華肝臟病雜志;2016年01期
2 陳成偉;成軍;竇曉光;段維佳;段鐘平;范建高;傅青春;高春芳;侯金森;胡和平;胡錫琪;黃建榮;韓濤;韓英;賈繼東;陸倫根;劉玉蘭;馬雄;茅益民;南月敏;?∑;邱德凱;任紅;尚佳;唐紅;王貴強(qiáng);王吉耀;王建設(shè);王磊;王宇明;魏來;許建明;徐銘益;謝青;謝渭芬;徐小元;楊長青;楊云生;尤紅;曾民德;張文宏;張躍新;周新民;莊輝;鄒曉平;;原發(fā)性膽汁性肝硬化(又名原發(fā)性膽汁性膽管炎)診斷和治療共識(shí)(2015)[J];臨床肝膽病雜志;2015年12期
3 于樂成;侯金林;;《2014年澳大利亞肝病學(xué)會(huì)專家共識(shí):瞬時(shí)彈性成像在慢性病毒性肝炎中的應(yīng)用建議》簡介[J];臨床肝膽病雜志;2015年04期
4 Xue-Xiu Zhang;Li-Feng Wang;Lei Jin;Yuan-Yuan Li;Shu-Li Hao;Yan-Chao Shi;Qing-Lei Zeng;Zhi-Wei Li;Zheng Zhang;George KK Lau;Fu-Sheng Wang;;Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients:Incidence and risk factors[J];World Journal of Gastroenterology;2015年12期
5 杜瑩;方蕾;;中藥湯劑/中成藥聯(lián)合熊去氧膽酸治療原發(fā)性膽汁性肝硬化療效的Meta分析[J];臨床肝膽病雜志;2015年01期
6 Satoshi Yamagiwa;Hiroteru Kamimura;Masaaki Takamura;Yutaka Aoyagi;;Autoantibodies in primary biliary cirrhosis:Recent progress in research on the pathogenetic and clinical significance[J];World Journal of Gastroenterology;2014年10期
7 劉紅虹;福軍亮;徐軍;羅生強(qiáng);劉振文;王福生;;123例原發(fā)性膽汁性肝硬化臨床表現(xiàn)與自身抗體譜[J];北京大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2013年02期
8 ;B cell depletion in treating primary biliary cirrhosis:Pros and cons[J];World Journal of Gastroenterology;2012年30期
9 王培之;華文浩;劉穎;;抗著絲點(diǎn)抗體與抗核抗體在原發(fā)性膽汁性肝硬化的臨床意義[J];北京醫(yī)學(xué);2012年06期
10 史旭華;張奉春;張p,
本文編號(hào):2139659
本文鏈接:http://sikaile.net/yixuelunwen/xiaohjib/2139659.html